These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17612006)

  • 21. [Lapatinib treatment-option in trastuzumab-resistant breast cancer].
    Pikó B
    Magy Onkol; 2009 Dec; 53(4):369-75. PubMed ID: 20071309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
    Romero Carreño E; Marcos Rodríguez JA; Santana Martínez S; de la Cruz Merino L
    Farm Hosp; 2016 Mar; 40(2):134-6. PubMed ID: 26980172
    [No Abstract]   [Full Text] [Related]  

  • 23. No cure in sight for the world's drug problem.
    Holmes D
    Lancet Oncol; 2009 May; 10(5):450. PubMed ID: 19418615
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
    Thallinger C; Lang I; Kuhar CG; Bartsch R; Singer CF; Petruzelka L; Melichar B; Knittelfelder R; Brodowicz T; Zielinski C
    BMC Cancer; 2016 Feb; 16():121. PubMed ID: 26887956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review.
    Yip AY; Tse LA; Ong EY; Chow LW
    Anticancer Drugs; 2010 Jun; 21(5):487-93. PubMed ID: 20220514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.
    Burstein HJ; Storniolo AM; Franco S; Forster J; Stein S; Rubin S; Salazar VM; Blackwell KL
    Ann Oncol; 2008 Jun; 19(6):1068-74. PubMed ID: 18283035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Advances in research on treatment of breast cancer with lapatinib].
    Ma CD; Shen KW; Shen ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):321-4. PubMed ID: 18953827
    [No Abstract]   [Full Text] [Related]  

  • 28. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
    Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
    Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
    Blackwell KL; Pegram MD; Tan-Chiu E; Schwartzberg LS; Arbushites MC; Maltzman JD; Forster JK; Rubin SD; Stein SH; Burstein HJ
    Ann Oncol; 2009 Jun; 20(6):1026-31. PubMed ID: 19179558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lapatinib.
    Moy B; Kirkpatrick P; Kar S; Goss P
    Nat Rev Drug Discov; 2007 Jun; 6(6):431-2. PubMed ID: 17633789
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.
    Molina-Garrido MJ; Guillen-Ponce C; Mora-Rufete A
    Anticancer Agents Med Chem; 2014 Jun; 14(5):639-45. PubMed ID: 23438846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
    Sardesai SD; Storniolo AM
    Womens Health (Lond); 2015 Jun; 11(3):281-94. PubMed ID: 26102468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lapatinib for breast cancer: a review of the current literature.
    MacFarlane RJ; Gelmon KA
    Expert Opin Drug Saf; 2011 Jan; 10(1):109-21. PubMed ID: 21091041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of lapatinib resistance in HER2-driven breast cancer.
    D'Amato V; Raimondo L; Formisano L; Giuliano M; De Placido S; Rosa R; Bianco R
    Cancer Treat Rev; 2015 Dec; 41(10):877-83. PubMed ID: 26276735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 36. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
    Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
    Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
    Parma J; Pavlick A; Schiff R; Osborne CK; Chang JC; Rimawi M; Trivedi MV
    Pharmacotherapy; 2013 Oct; 33(10):1126-9. PubMed ID: 23744830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.
    Boyle FM; Smith IE; O'Shaughnessy J; Ejlertsen B; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Amonkar M; Huang Y; Rappold E; Williams LS; Wang-Silvanto J; Kaneko T; Finkelstein DM; Goss PE;
    Eur J Cancer; 2015 Apr; 51(6):685-96. PubMed ID: 25752740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lapatinib: a competitor or companion to trastuzumab?
    Collins D; Hill AD; Young L
    Cancer Treat Rev; 2009 Nov; 35(7):574-81. PubMed ID: 19748186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer.
    Mutlu H; Büyükçelik A; Akça Z; Erden A
    J Oncol Pharm Pract; 2015 Feb; 21(1):72-3. PubMed ID: 24154651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.